ONCOLOGY: February 2009 Volume 23 Number 2 Supplement 1

Ensuring Holistic, Individualized Transitions of Care for Cancer Survivors

Real-world data from the P-VERIFY study didn’t find any notable OS improvements between multiple CDK4/6 inhibitor combos in metastatic breast cancer.

Andrew M. Evens, DO, MBA, MSc

December 9th 2024

Data Support Real-World Use of Ide-cel in R/R CNS Multiple Myeloma

Andrew M. Evens, DO, MBA, MSc, discusses the importance of meeting the emotional and physical needs of cancer survivors to help them lead fruitful lives.

$Real-world data show that CAR T-cell therapy may be considered for eligible patients with relapsed/refractory multiple myeloma harboring CNS involvement.$

Jonah Feldman

Managing Risks, Planning Treatment, & Making Progress in Pancreatic Cancer

Real-world data show that CAR T-cell therapy may be considered for eligible patients with relapsed/refractory multiple myeloma harboring CNS involvement.

A nurse practitioner discussed risk factors, diagnostic challenges, and treatment planning in patients with pancreatic cancers.

Kelley A. Rone, DNP, RN, AGNP-c

December 2nd 2024

Early Breast Cancer Treatment Post the CDK4/6 Inhibitor Ribociclib’s FDA Approval

A nurse practitioner discussed risk factors, diagnostic challenges, and treatment planning in patients with pancreatic cancers.

Darlene Dobkowski, MA

Navtemadlin Shows Efficacy, Safety in Relapsed/Refractory Myelofibrosis

During an FDA Special Session, field experts talked about the NATALEE trial and further information gathering on adjuvant ribociclib in breast cancer.

$Navtemadlin yields improvements in symptom score reductions ad spleen volume reduction among patients with relapsed/refractory myelofibrosis.$

Alex Biese

Real-World Data Show No OS Difference Among CDK4/6 Inhibitor Combos in HR+/HER2– MBC

Navtemadlin yields improvements in symptom score reductions ad spleen volume reduction among patients with relapsed/refractory myelofibrosis.

Related Content

Morgan Bayer

Ensuring Holistic, Individualized Transitions of Care for Cancer Survivors

Real-world data from the P-VERIFY study didn’t find any notable OS improvements between multiple CDK4/6 inhibitor combos in metastatic breast cancer.

Andrew M. Evens, DO, MBA, MSc

December 9th 2024

Data Support Real-World Use of Ide-cel in R/R CNS Multiple Myeloma

Andrew M. Evens, DO, MBA, MSc, discusses the importance of meeting the emotional and physical needs of cancer survivors to help them lead fruitful lives.

$Real-world data show that CAR T-cell therapy may be considered for eligible patients with relapsed/refractory multiple myeloma harboring CNS involvement.$

Jonah Feldman

Managing Risks, Planning Treatment, & Making Progress in Pancreatic Cancer

Real-world data show that CAR T-cell therapy may be considered for eligible patients with relapsed/refractory multiple myeloma harboring CNS involvement.

Kelley A. Rone, DNP, RN, AGNP-c

December 2nd 2024

Early Breast Cancer Treatment Post the CDK4/6 Inhibitor Ribociclib’s FDA Approval

A nurse practitioner discussed risk factors, diagnostic challenges, and treatment planning in patients with pancreatic cancers.

Darlene Dobkowski, MA

Navtemadlin Shows Efficacy, Safety in Relapsed/Refractory Myelofibrosis

During an FDA Special Session, field experts talked about the NATALEE trial and further information gathering on adjuvant ribociclib in breast cancer.

$Navtemadlin yields improvements in symptom score reductions ad spleen volume reduction among patients with relapsed/refractory myelofibrosis.$

Alex Biese